文章：

镥放射性配体疗法在前列腺癌中的作用

Role of Lutetium Radioligand Therapy in Prostate Cancer

原文发布日期：1 July 2024

DOI: 10.3390/cancers16132433

类型: Article

开放获取: 是

英文摘要：

Theranostics utilize ligands that chelate radionuclides and selectively bind with cancer-specific membrane antigens. In the case of prostate cancer (PCa), the state-of-the-art lutetium-177-PSMA combines the radioactive β-emitter177Lu with Vipivotide Tetraxetan, a prostate-specific membrane antigen (PSMA)-binding ligand. Several studies have been conducted, and the therapy is not without adverse effects (e.g., xerostomia, nausea, and fatigue); however, few events are reported as severe. The available evidence supports the use of177Lu-PSMA in selected metastatic castration-resistant prostate cancer patients, and the treatment is considered a standard of care in several clinical scenarios. Emerging research shows promising results in the setting of hormone-sensitive prostate cancer; however, evidence from high-quality controlled trials is still missing. In this review, we discuss the available evidence for the application of177Lu-PSMA in the management of PCa patients.

摘要翻译： 

诊疗学利用能够螯合放射性核素并选择性结合癌症特异性膜抗原的配体。在前列腺癌领域，最先进的镥-177-PSMA疗法将放射性β发射体177Lu与前列腺特异性膜抗原结合配体Vipivotide Tetraxetan相结合。多项研究已证实该疗法存在不良反应（如口干、恶心和疲劳），但严重事件报道较少。现有证据支持在特定转移性去势抵抗性前列腺癌患者中使用177Lu-PSMA，该疗法已被视为多种临床情境下的标准治疗方案。新兴研究显示其在激素敏感性前列腺癌治疗中前景广阔，但目前仍缺乏高质量对照试验的证据支持。本综述将系统探讨177Lu-PSMA在前列腺癌患者治疗中应用的现有证据。

原文链接：

Role of Lutetium Radioligand Therapy in Prostate Cancer